What is Certara?
Biosimulation software and drug-development services company with 2026 revenue growth guidance of 0%-4%; 2,400+ clients scale.
- Category
- Biosimulation software and drug-development services
- Headquarters
- Radnor, PA
- Founded
- 2008
- Employees
- 1,400+
- Total funding
- Public company; not venture-round led
- Status
- Nasdaq: CERT
What is Certara?
Certara is a Biosimulation software and drug-development services company headquartered in Radnor, PA. As of June 2026, its clearest scale signal is 2026 revenue growth guidance of 0%-4%; 2,400+ clients.
Certara operates a model-informed drug development platform serving more than 2,400 biopharma, academic, and regulatory clients across 70 countries. Its core customer set includes biopharmaceutical companies, CROs, academic institutions, regulatory agencies, clinical pharmacology teams, and drug-development executives, and its public product surface includes Phoenix, Simcyp, D360, Pirana, Certara Cloud. The current scale signal is 2026 revenue growth guidance of 0%-4%; 2,400+ clients, which makes this a mid-market public account with real enterprise procurement capacity rather than an early-stage startup.
The company competes where healthcare buyers care about evidence, reliability, compliance, integrations, and measurable operational or clinical outcomes. Vendor evaluation usually involves business owners plus finance, security, legal, procurement, data, clinical, quality, compliance, and IT stakeholders.
For sellers, the account should be approached as a public-company buying center. The strongest angles connect directly to growth, retention, margin expansion, reimbursement, quality, member or patient experience, regulated data handling, workflow automation, or lower cost to serve.
What does Certara offer?
Certara offers Phoenix, Simcyp, D360, Pirana and related healthcare workflows.
- Phoenix· Core product
- Simcyp· Core product
- D360· Core product
- Pirana· Workflow
- Certara Cloud· Workflow
- Biosimulation services· Workflow
- Regulatory science· Platform
- Market access and HEOR· Platform
- Drug-development consulting· Platform
How does Certara make money?
Certara earns software subscription, renewal, services, and consulting revenue from model-informed drug development, clinical pharmacology, regulatory, and market-access workflows.
Certara earns software subscription, renewal, services, and consulting revenue from model-informed drug development, clinical pharmacology, regulatory, and market-access workflows. Growth is driven by the same operating levers buyers track internally: customer volume, recurring revenue, utilization, reimbursement, renewal rates, attach rates, product expansion, and disciplined cost control.
Software and services are priced by product module, named users, enterprise license scope, hosted deployment, consulting hours, study complexity, and regulatory submission needs. In practice, commercial packaging usually separates strategic enterprise accounts, standard commercial customers, implementation services, support, usage, and renewal economics.
For a seller, budget access depends on showing a near-term connection to revenue capture, margin improvement, compliance, uptime, provider or member experience, data quality, clinical evidence, or workflow throughput. Generic efficiency claims are weaker than quantified impact on one of those operating levers.
Who leads Certara?
Certara is led by William F. Feehery, with finance, product, clinical, technology, commercial, and operations leaders influencing major vendor decisions.
- William F. FeeheryChief Executive OfficerCEOLeads Certara's biosimulation software and services strategy.
- John GallagherChief Financial OfficerCFO through announced 2026 transitionOwns finance during the announced CFO transition.
- Leif PedersenPresident, SoftwareSoftware executiveLeads software product and commercial strategy.
- Patrick SmithPresident, Drug Development SolutionsServices executiveLeads drug-development consulting and services.
How do you contact Certara's leadership?
Certara publishes an official investor-relations or corporate contact route, but this profile does not present guessed personal executive emails as verified. Use the official contact listed here, the company contact page, or a relationship-based introduction for executive outreach.
ir@certara.com (official published/company IR contact); personal executive format not verifiedHow much funding has Certara raised?
Certara is a public company (Nasdaq: CERT), so the current capital story is public-market status, operating cash flow, debt or equity access, and acquisitions rather than a private startup round stack.
2008: Founded - Certara forms through the combination of biosimulation and drug-development software assets. 2017: EQT acquisition - Private-equity ownership supports product and services expansion. 2020: IPO - Certara lists on Nasdaq under CERT. 2025: Portfolio focus - Certara continues shift toward proprietary software and model-informed drug development. 2026: CFO transition - Certara announces CFO transition while reaffirming 2026 guidance.
As of June 2026, Certara's practical funding capacity is best read through Nasdaq: CERT, 2026 revenue growth guidance of 0%-4%; 2,400+ clients, its latest annual or quarterly filings, cash flow, balance sheet, and guidance. For public mid-market healthcare companies, the next budget cycle is usually governed by operating plans and investor commitments, not by a new venture round.
Seller signal: public-company status gives Certara access to mature procurement and repeat budget cycles, but it also raises the proof bar. Successful pitches need a measurable business case, clean implementation plan, security and compliance readiness, and executive sponsorship from the functional owner.
How did Certara get here?
Certara grew through founding, product expansion, public-market milestones, and its latest June 2026 operating update.
- 2008Company formedCertara combines model-informed development assets.
- 2014Simcyp growsPhysiologically based pharmacokinetic modeling becomes a core franchise.
- 2020Public listingCertara lists on Nasdaq.
- 2023Cloud and software expansionThe company invests in hosted software and workflow products.
- 2025Writing-business divestitureCertara sharpens focus on biosimulation and technology.
- 2026CFO transitionCertara announces a finance leadership transition and reaffirms guidance.
Who are Certara's competitors?
Certara competes with public companies, private healthcare platforms, software vendors, services firms, and specialized workflow providers depending on the buyer's problem.
- Simulations PlusModeling and simulation software competitor.
- Dassault Systemes BIOVIAScientific informatics and modeling software competitor.
- Chemical Computing GroupMolecular modeling and computational chemistry software competitor.
- IQVIALarge life-sciences data, consulting, and technology competitor.
- ICONCRO and drug-development services competitor.
- SchrödingerComputational chemistry and drug-discovery software peer.
Certara — frequently asked questions
